BioStock: WntResearch increases the focus on Foxy-5

Early this week, WntResearch published its 2020 year-end report, and BioStock has taken a closer look at the most important points. The company was significantly affected by the health care reprioritisations resulting from the Covid-19 pandemic. Going forward the company is focusing on its main project Foxy-5 and carrying out the ongoing phase II study NeoFox. At the same time, WntResearch intends to carry out a rights issue in order to finance the continued work. BioStock has spoken to acting CEO Anders Rabbe to find out more.

Read the full article at biostock.se:

https://www.biostock.se/en/wntresearch-increases-the-focus-on-foxy-5/

This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se